BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26952044)

  • 41. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
    Park JE; Chun SE; Reichel D; Min JS; Lee SC; Han S; Ryoo G; Oh Y; Park SH; Ryu HM; Kim KB; Lee HY; Bae SK; Bae Y; Lee W
    PLoS One; 2017; 12(3):e0173247. PubMed ID: 28273121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension.
    Liu Y; Tian H; Yan X; Fan F; Wang W; Han J
    Exp Lung Res; 2013 Mar; 39(2):70-9. PubMed ID: 23301505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension.
    Dromparis P; Paulin R; Stenson TH; Haromy A; Sutendra G; Michelakis ED
    Circulation; 2013 Jan; 127(1):115-25. PubMed ID: 23149668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
    Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
    Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
    Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
    Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension.
    Sakao S; Tatsumi K
    Respiration; 2011; 81(3):253-61. PubMed ID: 21116108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway.
    Huang X; Zou L; Yu X; Chen M; Guo R; Cai H; Yao D; Xu X; Chen Y; Ding C; Cai X; Wang L
    J Mol Cell Cardiol; 2015 May; 82():153-66. PubMed ID: 25772255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.
    Luan Y; Chao S; Ju ZY; Wang J; Xue X; Qi TG; Cheng GH; Kong F
    Int Immunopharmacol; 2015 May; 26(1):188-93. PubMed ID: 25601497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.
    Abid S; Houssaïni A; Mouraret N; Marcos E; Amsellem V; Wan F; Dubois-Randé JL; Derumeaux G; Boczkowski J; Motterlini R; Adnot S
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):304-12. PubMed ID: 24334871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
    Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
    Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects and mechanism of oridonin on pulmonary hypertension induced by chronic hypoxia-hypercapnia in rats.
    Wang LX; Sun Y; Chen C; Huang XY; Lin Q; Qian GQ; Dong W; Chen YF
    Chin Med J (Engl); 2009 Jun; 122(12):1380-7. PubMed ID: 19567157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chlorogenic acid inhibits hypoxia-induced pulmonary artery smooth muscle cells proliferation via c-Src and Shc/Grb2/ERK2 signaling pathway.
    Li QY; Zhu YF; Zhang M; Chen L; Zhang Z; Du YL; Ren GQ; Tang JM; Zhong MK; Shi XJ
    Eur J Pharmacol; 2015 Mar; 751():81-8. PubMed ID: 25666384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
    Dahal BK; Cornitescu T; Tretyn A; Pullamsetti SS; Kosanovic D; Dumitrascu R; Ghofrani HA; Weissmann N; Voswinckel R; Banat GA; Seeger W; Grimminger F; Schermuly RT
    Am J Respir Crit Care Med; 2010 Jan; 181(2):158-67. PubMed ID: 19850946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
    Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
    J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting cell motility in pulmonary arterial hypertension.
    Paulin R; Meloche J; Courboulin A; Lambert C; Haromy A; Courchesne A; Bonnet P; Provencher S; Michelakis ED; Bonnet S
    Eur Respir J; 2014 Feb; 43(2):531-44. PubMed ID: 23845719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Involvement of Gax gene in hypoxia-induced pulmonary hypertension, proliferation, and apoptosis of arterial smooth muscle cells.
    Xia S; Tai X; Wang Y; An X; Qian G; Dong J; Wang X; Sha B; Wang D; Murthi P; Kalionis B; Wang X; Bai C
    Am J Respir Cell Mol Biol; 2011 Jan; 44(1):66-73. PubMed ID: 20160044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Involvement of CapG in proliferation and apoptosis of pulmonary arterial smooth muscle cells and in hypoxia-induced pulmonary hypertension rat model.
    Xu X; Hu H; Wang X; Ye W; Su H; Hu Y; Dong L; Zhang R; Ying K
    Exp Lung Res; 2016 Apr; 42(3):142-53. PubMed ID: 27093378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
    Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
    Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role for DNA damage signaling in pulmonary arterial hypertension.
    Meloche J; Pflieger A; Vaillancourt M; Paulin R; Potus F; Zervopoulos S; Graydon C; Courboulin A; Breuils-Bonnet S; Tremblay E; Couture C; Michelakis ED; Provencher S; Bonnet S
    Circulation; 2014 Feb; 129(7):786-97. PubMed ID: 24270264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.